SINT vs. BJDX, MOTS, OSAP, OSA, RSLS, NMRD, DYNT, QNRX, INVO, and TNON
Should you be buying Sintx Technologies stock or one of its competitors? The main competitors of Sintx Technologies include Bluejay Diagnostics (BJDX), Motus GI (MOTS), ProSomnus (OSAP), ProSomnus (OSA), ReShape Lifesciences (RSLS), Nemaura Medical (NMRD), Dynatronics (DYNT), Quoin Pharmaceuticals (QNRX), INVO Bioscience (INVO), and Tenon Medical (TNON). These companies are all part of the "surgical & medical instruments" industry.
Bluejay Diagnostics (NASDAQ:BJDX) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.
Bluejay Diagnostics has a net margin of 0.00% compared to Bluejay Diagnostics' net margin of -314.39%. Bluejay Diagnostics' return on equity of -67.12% beat Sintx Technologies' return on equity.
Bluejay Diagnostics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Sintx Technologies has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
In the previous week, Sintx Technologies' average media sentiment score of 0.00 equaled Bluejay Diagnostics'average media sentiment score.
Sintx Technologies received 34 more outperform votes than Bluejay Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Bluejay Diagnostics an outperform vote while only 61.02% of users gave Sintx Technologies an outperform vote.
18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 47.0% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 0.8% of Sintx Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Sintx Technologies has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Sintx Technologies beats Bluejay Diagnostics on 8 of the 13 factors compared between the two stocks.
Get Sintx Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SINT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sintx Technologies Competitors List
Related Companies and Tools
